Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Infosys Limited — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Infosys Limited trades at $11.77 (market cap $44.92B). The key difference: Infosys Limited is far larger — about 15.7× Dyne Therapeutics Inc. Common Stock's market cap, and Infosys Limited pays a 4.59% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Infosys Limited for 26 Days on average.
| DYN | INFY | |
|---|---|---|
Market Cap | $2.86B | $44.92B |
Volume | 3,341,579 | 25,564,570 |
Sector | Health | Technology |
52-Week High | $26.78 | $20.22 |
52-Week Low | $14.60 | $10.49 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $2.18B | $42.66B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
INFY trades at $11.40, up 5.26% today, with a bullish technical signal driven by oversold RSI conditions. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations. Revenue for 2025 was $19.28B, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro, positioning the firm for innovation-driven growth.
The outlook is cautiously optimistic, supported by solid profitability and strategic partnerships, but tempered by a mixed analyst consensus and potential net cash flow decline in 2026. Key risks include competitive pressures in IT services and macroeconomic sensitivity. The consensus price target of $11.48 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
